BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 37446214)

  • 21. A Population-Based Assessment of the Impact of 7- and 13-Valent Pneumococcal Conjugate Vaccines on Macrolide-Resistant Invasive Pneumococcal Disease: Emergence and Decline of Streptococcus pneumoniae Serotype 19A (CC320) With Dual Macrolide Resistance Mechanisms.
    Schroeder MR; Chancey ST; Thomas S; Kuo WH; Satola SW; Farley MM; Stephens DS
    Clin Infect Dis; 2017 Sep; 65(6):990-998. PubMed ID: 28903506
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Bradshaw JL; Caballero AR; Bierdeman MA; Adams KV; Pipkins HR; Tang A; O'Callaghan RJ; McDaniel LS
    mSphere; 2018; 3(3):. PubMed ID: 29720526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Urinary pneumococcal or Legionella antigen detection tests and low-spectrum antibiotic therapy for community-acquired pneumonia].
    Roger PM; Risso K; Hyvernat H; Landraud L; Vassallo M; Dellamonica J; de Salvador F; Cua E; Bernardin G
    Med Mal Infect; 2010 Jun; 40(6):347-51. PubMed ID: 20172672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia.
    Feldman C
    J Lab Clin Med; 2004 May; 143(5):269-83. PubMed ID: 15122171
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recalibrated estimates of non-bacteremic and bacteremic pneumococcal community acquired pneumonia in hospitalized Canadian adults from 2010 to 2017 with addition of an extended spectrum serotype-specific urine antigen detection assay.
    LeBlanc JJ; ElSherif M; Ye L; MacKinnon-Cameron D; Ambrose A; Hatchette TF; Lang ALS; Gillis HD; Martin I; Demczuk WHB; Andrew MK; Boivin G; Bowie W; Green K; Johnstone J; Loeb M; McCarthy AE; McGeer A; Semret M; Trottier S; Valiquette L; Webster D; McNeil SA
    Vaccine; 2022 Apr; 40(18):2635-2646. PubMed ID: 35315326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Invasive pneumococcal disease among children in rural Bangladesh: results from a population-based surveillance.
    Arifeen SE; Saha SK; Rahman S; Rahman KM; Rahman SM; Bari S; Naheed A; Mannan I; Seraji MH; Ahmed NU; Hassan MS; Huda N; Siddik AU; Quasem I; Islam M; Fatima K; Al-Emran H; Brooks WA; Baqui AH; Breiman RF; Sack D; Luby SP
    Clin Infect Dis; 2009 Mar; 48 Suppl 2():S103-13. PubMed ID: 19191605
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pneumococcal community-acquired pneumonia in 148 hospitalized adult patients.
    Porath A; Schlaeffer F; Pick N; Leinonen M; Lieberman D
    Eur J Clin Microbiol Infect Dis; 1997 Dec; 16(12):863-70. PubMed ID: 9495665
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pneumococcal virulence factors in community-acquired pneumonia.
    Feldman C; Anderson R
    Curr Opin Pulm Med; 2020 May; 26(3):222-231. PubMed ID: 32149750
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia.
    Lynch III JP; Martinez FJ
    Clin Infect Dis; 2002 Mar; 34 Suppl 1():S27-46. PubMed ID: 11810608
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increase of Macrolide-Resistance in
    Gonzales BE; Mercado EH; Pinedo-Bardales M; Hinostroza N; Campos F; Chaparro E; Del Águila O; Castillo ME; Saenz A; Reyes I; Ochoa TJ
    Front Cell Infect Microbiol; 2022; 12():866186. PubMed ID: 35615398
    [No Abstract]   [Full Text] [Related]  

  • 31. Understanding the burden of pneumococcal disease in adults.
    Blasi F; Mantero M; Santus P; Tarsia P
    Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():7-14. PubMed ID: 22882668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Review manuscript: Mechanisms of platelet activation by the pneumococcus and the role of platelets in community-acquired pneumonia.
    Anderson R; Feldman C
    J Infect; 2017 Dec; 75(6):473-485. PubMed ID: 28943342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bacteremic pneumococcal pneumonia associated with macrolide failure.
    Dylewski J; Davidson R
    Eur J Clin Microbiol Infect Dis; 2006 Jan; 25(1):39-42. PubMed ID: 16411124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. International prevalence and risk factors evaluation for drug-resistant Streptococcus pneumoniae pneumonia.
    Aliberti S; Cook GS; Babu BL; Reyes LF; H Rodriguez A; Sanz F; Soni NJ; Anzueto A; Faverio P; Sadud RF; Muhammad I; Prat C; Vendrell E; Neves J; Kaimakamis E; Feneley A; Swarnakar R; Franzetti F; Carugati M; Morosi M; Monge E; Restrepo MI;
    J Infect; 2019 Oct; 79(4):300-311. PubMed ID: 31299410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Macrolides Decrease the Proinflammatory Activity of Macrolide-Resistant Streptococcus pneumoniae.
    Domon H; Hirayama S; Isono T; Sasagawa K; Takizawa F; Maekawa T; Yanagihara K; Terao Y
    Microbiol Spectr; 2023 Jun; 11(3):e0014823. PubMed ID: 37191519
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Streptococcus pneumoniae: epidemiology and patterns of resistance.
    Jacobs MR
    Am J Med; 2004 Aug; 117 Suppl 3A():3S-15S. PubMed ID: 15360092
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability.
    Lode H; File TM; Mandell L; Ball P; Pypstra R; Thomas M;
    Clin Ther; 2002 Nov; 24(11):1915-36. PubMed ID: 12501883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pneumococcal epidemiology among us adults hospitalized for community-acquired pneumonia.
    Isturiz RE; Ramirez J; Self WH; Grijalva CG; Counselman FL; Volturo G; Ostrosky-Zeichner L; Peyrani P; Wunderink RG; Sherwin R; Overcash JS; Oliva SP; File T; Wiemken TL; McLaughlin JM; Pride MW; Gray S; Alexander R; Ford KD; Jiang Q; Jodar L
    Vaccine; 2019 May; 37(25):3352-3361. PubMed ID: 31072732
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Streptococcus pneumoniae: does antimicrobial resistance matter?
    Lynch JP; Zhanel GG
    Semin Respir Crit Care Med; 2009 Apr; 30(2):210-38. PubMed ID: 19296420
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Re-evaluation of the therapy of severe pneumonia caused by Streptococcus pneumoniae.
    Plouffe JF; Martin DR
    Infect Dis Clin North Am; 2004 Dec; 18(4):963-74; x-xi. PubMed ID: 15555834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.